![]() Trimethoprim (top) and sulfamethoxazole (bottom) | |
Combination of | |
---|---|
Sulfamethoxazole | Sulfonamide antibiotic |
Trimethoprim | Dihydrofolate reductase inhibitor |
Clinical data | |
Trade names | Bactrim, Cotrim, Septra, others |
Other names | TMP/SMX, cotrimoxazole, Co-trimoxazole (BAN UK) |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | oral, intravenous [2] |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
(verify) |
Trimethoprim/sulfamethoxazole, sold under the brand name Bactrim among others, is a fixed-dose combination antibiotic medication used to treat a variety of bacterial infections. [2] It consists of one part trimethoprim to five parts sulfamethoxazole. [7] It is used to treat urinary tract infections, methicillin-resistant Staphylococcus aureus (MRSA) skin infections, travelers' diarrhea, respiratory tract infections, and cholera, among others. [2] [7] It is used both to treat and prevent pneumocystis pneumonia and toxoplasmosis in people with HIV/AIDS and other causes of immunosuppression. [2] It can be given orally (swallowed by mouth) or intravenous infusion (slowly injected into a vein with an IV). [2]
Trimethoprim/sulfamethoxazole is on the World Health Organization's List of Essential Medicines. [8] It is available as a generic medication. [7] [9] In 2021, it was the 122nd most commonly prescribed medication in the United States, with more than 4 million prescriptions. [10] [11] [ United States-centric ]
Trimethoprim/sulfamethoxazole generally kills bacteria, [2] by blocking the microorganisms' ability to make and to use folate. [2]
Trimethoprim/sulfamethoxazole (TMP/SMX) is the medicine most commonly used to prevent Pneumocystis jirovecii pneumonia (PCP) [12] People who get Pneumocystis pneumonia have a medical condition that weakens their immune system, like HIV/AIDS, or take medicines (such as corticosteroid,mono clonal antibody,immunosuppressants) that reduce the body's ability to fight bacterial and viral infections. People with HIV/AIDS are less likely to get Pneumocystis pneumonia as a result of antiretroviral therapy (ART). However, Pneumocystis pneumonia is still a substantial public health problem. Most of what is scientifically known about Pneumocystis pneumonia and its treatment comes from studying people with HIV/AIDS. [12]
Organisms against which trimethoprim/sulfamethoxazole can be effective include: [13] [14]
The only notable nonsusceptible organisms are Pseudomonas aeruginosa , the mycoplasmae [14] and Francisella tularensis (the causative organism of tularaemia). [15] [16]
Its use during pregnancy is contraindicated, although it has been placed in Australian pregnancy category C. [13] Its use during the first trimester (during organogenesis) and 12 weeks prior to pregnancy has been associated with an increased risk of congenital malformations, especially malformations associated with maternal folic acid deficiency (which is most likely related to the mechanism of action of co-trimoxazole) such as neural tube defects such as spina bifida, cardiovascular malformations (e.g. Ebstein's anomaly), urinary tract defects, oral clefts, and club foot in epidemiological studies. [13] Its use later on during pregnancy also increases the risk of preterm labour (odds ratio: 1.51) and low birth weight (odds ratio: 1.67). [17] [18] Animal studies have yielded similarly discouraging results. [3]
It appears to be safe for use during breastfeeding as long as the baby is healthy. [19]
Its use in those less than 2 months of age is not recommended due to the risk of adverse side effects. [20]
Common side effects include nausea, vomiting, rash, and diarrhea. [2] Severe allergic reactions and Clostridium difficile infection may occasionally occur. [2] Its use in pregnancy is not recommended. [2] [19] It appears to be safe for use during breastfeeding as long as the baby is healthy. [19]
Contraindications include the following: [13] [5]
Its use is advised against in people being concomitantly treated with: [13] [3] [5] [6] [21] [22]
Likely signs of toxicity include: [3]
The recommended treatment for overdose includes: [3]
Alkalinisation of the urine may reduce the toxicity of sulfamethoxazole, but it may increase the toxic effects of trimethoprim. [3]
The synergy between trimethoprim and sulfamethoxazole was first described in the late 1960s. [25] [26] [27] Trimethoprim and sulfamethoxazole have a greater effect when given together than when given separately, because they inhibit successive steps in the folate synthesis pathway. They are given in a one-to-five ratio in their tablet formulations so that when they enter the body their concentration in the blood and tissues is roughly one-to-twenty — the exact ratio required for a peak synergistic effect between the two. [14]
Sulfamethoxazole, a sulfonamide, induces its therapeutic effects by interfering with the de novo (that is, from within the cell) synthesis of folate inside microbial organisms such as protozoa, fungi and bacteria. It does this by competing with p-aminobenzoic acid (PABA) in the biosynthesis of dihydrofolate. [14]
Trimethoprim serves as a competitive inhibitor of dihydrofolate reductase (DHFR), hence inhibiting the de novo synthesis of tetrahydrofolate, the biologically active form of folate. [14]
Tetrahydrofolate is crucial in the synthesis of purines, thymidine, and methionine which are needed for the production of DNA and proteins [28] during bacterial replication.
The effects of trimethoprim causes a backlog of dihydrofolate (DHF) and this backlog can work against the inhibitory effect the drug has on tetrahydrofolate biosynthesis. This is where the sulfamethoxazole comes in; its role is in depleting the excess DHF by preventing it from being synthesised in the first place. [14]
Co-trimoxazole was claimed to be more effective than either of its components individually in treating bacterial infections, although this was later disputed. [29] [30]
Component | Tmax (h) | Vd (L) | Protein binding | t1/2 (h) | Excretion |
---|---|---|---|---|---|
Sulfamethoxazole | 1-4 | 20 | 66% | 8-10 | Renal |
Trimethoprim | 1-4 | 130 | 42-45% | 10 | Renal |
Indication | ![]() FDA-labelled indication? | ![]() TGA-labelled indication? | ![]() MHRA-labelled indication? | Literature support |
---|---|---|---|---|
Acute infective exacerbation of COPD | Yes | No | No | Clinical trials are lacking. |
Prophylaxis in HIV-infected individuals | No | No | No | Effective in one Ugandan study on morbidity, mortality, CD4-cell count, and viral load in HIV infection. [31] |
Otitis media | Paediatric population only | No | Yes | Clinical trials have confirmed its efficacy in chronic active otitis media [32] and acute otitis media. [33] |
Travellers' diarrhoea, treatment & prophylaxis | Yes | No | No | Clinical trials have confirmed its efficacy as a treatment for travellers' diarrhoea. [34] [35] [36] |
Urinary tract infection | Yes | No | Yes | Clinical trials have confirmed its efficacy in this indication. [14] |
Bacterial infections | ||||
Acne vulgaris | No | No | No | At least one clinical trial supports its use in this indication. [37] |
Listeria | No | Yes | No | Well-designed clinical trials are lacking. |
Melioidosis | No | Yes | No | Clinical trials have confirmed its efficacy, with or without adjunctive doxycycline; although, co-trimoxazole alone seems preferable. [38] [39] [40] |
Pertussis (whooping cough) | No | No | No | One cochrane review supports its efficacy in preventing the spread of pertussis. [41] |
Shigellosis | Yes | Yes | No | Generally accepted treatment for shigellosis. [42] A recent Cochrane review found that while it is an effective treatment for shigellosis it also produces more significant adverse effects than other antibiotic drugs. [43] |
Staphylococcus aureus infections | No | No | No | In vitro and in vivo activity against both non-resistant and methicillin-resistant Staphylococcus aureus (MRSA) infections. [44] [45] [46] [47] [48] [49] [50] |
Tuberculosis | No | No | No | In vitro and in vivo activity against both nonresistant and MDR strains of TB. [51] [52] [53] |
Whipple's disease | No | No | No | Co-trimoxazole is the recommended standard treatment for whipple's disease in some treatment protocols. [54] [55] [56] |
Fungal and protozoal infections | ||||
Isosporiasis | No | No | No | Clinical trials have confirmed its use in this indication. [57] |
Malaria | No | No | No | Clinical trials have confirmed its efficacy in both the treatment and prevention of malaria. [58] |
Pneumocystis jirovecii pneumonia | Yes | Yes | Yes | Its use as a prophylactic treatment is supported by one clinical trial involving children with acute lymphoblastic leukaemia. [59] Other than this and one other clinical trial into its efficacy as a treatment for pneumocystis pneumonia, [60] data on its use in both the treatment and prevention of pneumocystis pneumonia is significantly lacking. |
Toxoplasmosis | Yes | Prevention only | Yes | Clinical trials have confirmed its prophylactic and therapeutic utility in cases of toxoplasmosis. [61] [62] [63] [64] [65] [66] |
Trimethoprim/sulfamethoxazole may be abbreviated as SXT, SMZ-TMP, TMP-SMX, TMP-SMZ, or TMP-sulfa.[ citation needed ] The generic British Approved Name (BAN) Co-trimoxazole is used for trimethoprim/sulfamethoxazole manufactured and sold by many different companies. [67]
The following list of brand names is incomplete:
Trimethoprim/sulfamethoxazole is relatively inexpensive as of 2019. [9]
Trimethoprim (TMP) is an antibiotic used mainly in the treatment of bladder infections. Other uses include for middle ear infections and travelers' diarrhea. With sulfamethoxazole or dapsone it may be used for Pneumocystis pneumonia in people with HIV/AIDS. It is taken orally.
Staphylococcus aureus is a gram-positive spherically shaped bacterium, a member of the Bacillota, and is a usual member of the microbiota of the body, frequently found in the upper respiratory tract and on the skin. It is often positive for catalase and nitrate reduction and is a facultative anaerobe, meaning that it can grow without oxygen. Although S. aureus usually acts as a commensal of the human microbiota, it can also become an opportunistic pathogen, being a common cause of skin infections including abscesses, respiratory infections such as sinusitis, and food poisoning. Pathogenic strains often promote infections by producing virulence factors such as potent protein toxins, and the expression of a cell-surface protein that binds and inactivates antibodies. S. aureus is one of the leading pathogens for deaths associated with antimicrobial resistance and the emergence of antibiotic-resistant strains, such as methicillin-resistant S. aureus (MRSA). The bacterium is a worldwide problem in clinical medicine. Despite much research and development, no vaccine for S. aureus has been approved.
Methicillin-resistant Staphylococcus aureus (MRSA) is a group of gram-positive bacteria that are genetically distinct from other strains of Staphylococcus aureus. MRSA is responsible for several difficult-to-treat infections in humans. It caused more than 100,000 deaths worldwide attributable to antimicrobial resistance in 2019.
Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics. Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA). The main uses are infections of the skin and pneumonia although it may be used for a variety of other infections including drug-resistant tuberculosis. It is used either by injection into a vein or by mouth.
The cephalosporins are a class of β-lactam antibiotics originally derived from the fungus Acremonium, which was previously known as Cephalosporium.
A hospital-acquired infection, also known as a nosocomial infection, is an infection that is acquired in a hospital or other healthcare facility. To emphasize both hospital and nonhospital settings, it is sometimes instead called a healthcare-associated infection. Such an infection can be acquired in a hospital, nursing home, rehabilitation facility, outpatient clinic, diagnostic laboratory or other clinical settings. A number of dynamic processes can bring contamination into operating rooms and other areas within nosocomial settings. Infection is spread to the susceptible patient in the clinical setting by various means. Healthcare staff also spread infection, in addition to contaminated equipment, bed linens, or air droplets. The infection can originate from the outside environment, another infected patient, staff that may be infected, or in some cases, the source of the infection cannot be determined. In some cases the microorganism originates from the patient's own skin microbiota, becoming opportunistic after surgery or other procedures that compromise the protective skin barrier. Though the patient may have contracted the infection from their own skin, the infection is still considered nosocomial since it develops in the health care setting. Nosocomial infection tends to lack evidence that it was present when the patient entered the healthcare setting, thus meaning it was acquired post-admission.
Fusidic acid, sold under the brand name Fucidin among others, is a steroid antibiotic that is often used topically in creams or ointments and eyedrops but may also be given systemically as tablets or injections. As of October 2008, the global problem of advancing antimicrobial resistance has led to a renewed interest in its use.
Vancomycin-resistant Staphylococcus aureus (VRSA) are strains of Staphylococcus aureus that have acquired resistance to the glycopeptide antibiotic vancomycin. Bacteria can acquire resistant genes either by random mutation or through the transfer of DNA from one bacterium to another. Resistance genes interfere with the normal antibiotic function and allow bacteria to grow in the presence of the antibiotic. Resistance in VRSA is conferred by the plasmid-mediated vanA gene and operon. Although VRSA infections are uncommon, VRSA is often resistant to other types of antibiotics and a potential threat to public health because treatment options are limited. VRSA is resistant to many of the standard drugs used to treat S. aureus infections. Furthermore, resistance can be transferred from one bacterium to another.
Tigecycline, sold under the brand name Tygacil, is a tetracycline antibiotic medication for a number of bacterial infections. It is a glycylcycline class drug that is administered intravenously. It was developed in response to the growing rate of antibiotic resistant bacteria such as Staphylococcus aureus, Acinetobacter baumannii, and E. coli. As a tetracycline derivative antibiotic, its structural modifications has expanded its therapeutic activity to include Gram-positive and Gram-negative organisms, including those of multi-drug resistance.
Atovaquone, sold under the brand name Mepron, is an antimicrobial medication for the prevention and treatment of Pneumocystis jirovecii pneumonia (PCP).
Dicloxacillin is a narrow-spectrum β-lactam antibiotic of the penicillin class. It is used to treat infections caused by susceptible (non-resistant) Gram-positive bacteria. It is active against beta-lactamase-producing organisms such as Staphylococcus aureus, which would otherwise be resistant to most penicillins. Dicloxacillin is available under a variety of trade names including Diclocil (BMS).
Oritavancin, sold under the brand name Orbactiv among others, is a semisynthetic glycopeptide antibiotic medication for the treatment of serious Gram-positive bacterial infections. Its chemical structure as a lipoglycopeptide is similar to vancomycin.
Cefoxitin is a second-generation cephamycin antibiotic developed by Merck & Co., Inc. from Cephamycin C in the year following its discovery, 1972. It was synthesized in order to create an antibiotic with a broader spectrum. It is often grouped with the second-generation cephalosporins. Cefoxitin requires a prescription and as of 2010 is sold under the brand name Mefoxin by Bioniche Pharma, LLC. The generic version of cefoxitin is known as cefoxitin sodium.
Ceftobiprole, sold under the brand name Zevtera among others, is a fifth-generation cephalosporin antibacterial used for the treatment of hospital-acquired pneumonia and community-acquired pneumonia. It is marketed by Basilea Pharmaceutica under the brand names Zevtera and Mabelio. Like other cephalosporins, ceftobiprole exerts its antibacterial activity by binding to important penicillin-binding proteins and inhibiting their transpeptidase activity which is essential for the synthesis of bacterial cell walls. Ceftobiprole has high affinity for penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus strains and retains its activity against strains that express divergent mecA gene homologues. Ceftobiprole also binds to penicillin-binding protein 2b in Streptococcus pneumoniae (penicillin-intermediate), to penicillin-binding protein 2x in Streptococcus pneumoniae (penicillin-resistant), and to penicillin-binding protein 5 in Enterococcus faecalis.
HIV disease–related drug reaction is an adverse drug reaction caused by drugs used for the treatment of HIV/AIDS.
Ceftaroline fosamil (INN), brand name Teflaro in the US and Zinforo in Europe, is a cephalosporin antibiotic with anti-MRSA activity. Ceftaroline fosamil is a prodrug of ceftaroline. It is active against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria. It retains some activity of later-generation cephalosporins having broad-spectrum activity against Gram-negative bacteria, but its effectiveness is relatively much weaker. It is currently being investigated for community-acquired pneumonia and complicated skin and skin structure infection.
Staphylococcus schleiferi is a Gram-positive, cocci-shaped bacterium of the family Staphylococcaceae. It is facultatively anaerobic, coagulase-variable, and can be readily cultured on blood agar where the bacterium tends to form opaque, non-pigmented colonies and beta (β) hemolysis. There exists two subspecies under the species S. schleiferi: Staphylococcus schleiferi subsp. schleiferi and Staphylococcus schleiferi subsp. coagulans.
Staphylococcus pseudintermedius is a gram positive coccus bacteria of the genus Staphylococcus found worldwide. It is primarily a pathogen for domestic animals, but has been known to affect humans as well. S. pseudintermedius is an opportunistic pathogen that secretes immune modulating virulence factors, has many adhesion factors, and the potential to create biofilms, all of which help to determine the pathogenicity of the bacterium. Diagnoses of Staphylococcus pseudintermedius have traditionally been made using cytology, plating, and biochemical tests. More recently, molecular technologies like MALDI-TOF, DNA hybridization and PCR have become preferred over biochemical tests for their more rapid and accurate identifications. This includes the identification and diagnosis of antibiotic resistant strains.
Decolonization, also bacterial decolonization, is a medical intervention that attempts to rid a patient of an antimicrobial resistant pathogen, such as methicillin-resistant Staphylococcus aureus (MRSA) or antifungal-resistant Candida.
Kerry L. LaPlante is an American pharmacist, academic and researcher. She is the Dean at the University of Rhode Island College of Pharmacy. She is a Professor of Pharmacy and former department Chair of the Department of Pharmacy Practice at the University of Rhode Island, an adjunct professor of medicine at Brown University, an Infectious Diseases Pharmacotherapy Specialist, and the Director of the Rhode Island Infectious Diseases Fellowship and Research Programs at the Veterans Affairs Medical Center in Providence, Rhode Island.
An extensive systematic review of sulfonamide usage near term and during breastfeeding found no side effects in infants; the authors concluded that use of this combination drug during breastfeeding presents no risk of neonatal kernicterus... LactMed: Use is considered acceptable when breastfeeding healthy, full-term infants after the newborn period